Ionizable Lipid Nanoparticles for Nucleic Acid Delivery
Solution Overview
Problem
The delivery of nucleic acids to cells is hindered by their instability and low cell permeability, necessitating improved methods and compositions for targeted and effective delivery of therapeutic and prophylactic agents.
Innovation Solution
Development of novel nanoparticle compositions comprising an ionizable lipid, a phospholipid, cholesterol, and a cholesterol derivative, such as β-sitosterol or stigmasterol, which modulate intracellular lipid transport to enhance cell uptake and expression of therapeutic nucleic acids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If nucleic acids are delivered directly to cells, then the therapeutic agent reaches the target, but the delivery efficiency is low due to instability and low cell permeability
Solution Approach 1:
The patent uses lipid nanoparticles as an intermediary carrier to deliver nucleic acids to cells. The nanoparticle composition includes ionizable lipids, phospholipids, cholesterol, and cholesterol derivatives that form protective carriers, enabling the unstable nucleic acids to be transported efficiently through biological barriers while maintaining their integrity until cellular uptake occurs.
Solution Approach 2:
The patent employs ionizable lipids that change their charge state based on pH conditions. These lipids are neutral at physiological pH but become positively charged in the acidic endosomal environment, enabling the nanoparticle to escape from endosomes and release the nucleic acid payload into the cytoplasm, thereby improving delivery efficiency.
2Productivity
If conventional lipid nanoparticle compositions are used, then some delivery capability is achieved, but safety and efficacy are insufficient
Solution Approach 1:
The patent creates a composite lipid nanoparticle system combining multiple lipid types (ionizable lipids, phospholipids, cholesterol) with specific cholesterol derivatives (phytosterols like β-sitosterol, stigmasterol, or campesterol). This composite structure enhances both delivery efficiency and safety by improving cellular uptake while reducing immunogenicity and toxicity compared to conventional single-lipid formulations.
Solution Approach 2:
The patent introduces specific cholesterol derivatives with particular structural characteristics (phytosterols with specific side chain configurations) to localize functional improvements within the nanoparticle structure. These specific components enhance cell membrane interaction and endosomal escape at specific locations within the nanoparticle, thereby improving overall efficacy while maintaining safety.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel nanoparticle compositions significantly increase the delivery efficiency and expression of therapeutic nucleic acids, offering enhanced therapeutic options for diseases characterized by dysfunctional protein activity.
Implementation Method 1
cholesterol and a cholesterol derivative, such as β-sitosterol or stigmasterol, which modulate intracellular lipid transport to enhance cell uptake
Implementation Method 2
enhance cell uptake and expression of therapeutic nucleic acids
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3A~3B
AI summary
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include an ionizable lipid, a phospholipid, a first sterol or a tocopherol, and optionally a second sterol different from the first sterol. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.